Enterprise Ireland signs new strategic alliance with Northwell Health
Northwell Health, the largest not-for-profit health system in the US Northeast, serving residents of New York and Connecticut, has signed a new strategic alliance with Enterprise Ireland.
Under the new agreement, Enterprise Ireland client companies will continue to benefit from direct access to Northwell’s leading clinical experts across its network of 28 hospitals and more than 1000 outpatient facilities, as well as introductions to Northwell’s innovation and commercial infrastructure.
Northwell Health is currently engaged with 18 Enterprise Ireland life sciences and health tech companies and has to date delivered tangible, measurable outcomes for these companies including procurement contracts, clinical pilots and trials, and strategic investments.
Enteprise Ireland-supported Shorla Oncology, Fire1, Head Diagnostics, and X-Bolt also announced plans to grow its presence in the US.
Elaine Brennan, executive director, global strategic partnerships, Northwell Health said: “Our international business programme has proven to be an invaluable gateway for innovative international companies seeking to enter and scale within the US healthcare market.”
This new alliance reflects Ireland’s emergence as a global hub in lifesciences and health technology innovation and investment. In 2024, according to PitchBook data, Ireland defied a global venture capital slowdown, recording €491 million in lifesciences and healthtech VC investment, a landmark achievement that underscores the strength of the Irish innovation ecosystem.
Enterprise Ireland’s support for Irish life sciences and health tech companies goes beyond capital. By forging deep institutional relationships with leading US health systems such as Northwell Health, Enterprise Ireland equips client companies with the clinical access, commercial expertise, and market credibility needed to succeed in the highly competitive US market.
Neurent Medical
Northwell Health also signed a partnership with Galway-based Neurent Medical, whose Neuromark technology has benefited from Northwell’s clinical network as the company scales across the US market. Neurent Medical recently closed an oversubscribed €62.5 million Series C funding round and is developing innovative, minimally invasive treatments for chronic rhinitis and other chronic inflammatory sinonasal diseases.
Neurent develops innovative, minimally invasive treatments for chronic inflammatory sinonasal diseases, with a particular focus on chronic rhinitis. The company’s proprietary Neuromark technology enables ENT physicians to precisely target and disrupt overactive autonomic nerves to reduce rhinitis symptoms through an in-office procedure, offering patients a clinically effective alternative to ongoing medication.
Enterprise Ireland has been a supporter of Neurent Medical since its early stages, providing a commercialisation grant that enabled the company’s foundational development, and subsequently participating in its Series A financing round.
In February 2026, Neurent Medical closed an oversubscribed Series C funding round raising €62.5 million. The round was led by MVM Partners with significant participation from Sofinnova Partners, and continued support from existing investors including EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland.
Northwell cares for more than 3 million people annually in the New York metro area, including Long Island, the Hudson Valley, western Connecticut and beyond.
TechCentral Reporters
Subscribers 0
Fans 0
Followers 0
Followers